UNSPSC 51422351: Mazipredone hydrochloride

This classification denotes a therapeutic glucocorticoid C26H38N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HOX0WI4U1F, chemically known as (11.beta.)-11,17-dihydroxy-21-(4-methyl-1-piperazinyl)pregna-1,4-diene-3,20-dione hydrochloride, but more generally known as mazipredone hydrochloride, which bears US NIH Compound Identifier 6063. European Medicines Agency schedules Mazipredone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14485MIG.

Most nations, for tariff and trade purposes, schedule mazipredone hydrochloride under HS 29372900 and SITC 54153. As of Q4 2014, MAZIPREDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CN4CCN(CC4)C)O)CCC5=CC(=O)C=C[C@]35C)O.CL.

UNSPSC 51422351 Mazipredone hydrochloride is a Commodity code representing pharmaceutical products procured by state and local health and human services agencies. The recent opportunities tagged under this code show little relevance to the code's nominal scope; the Seminole County, Florida solicitation (IFB60459723LAS) actually seeks naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission RFI (HHS0017013) addresses direct-to-manufacturer prescription fulfillment strategy rather than a specific pharmaceutical product. State and local issuers using pharmaceutical codes in this tier include county health departments, state health and human services commissions, and community health agencies. When pharmaceutical solicitations do align with their nominal UNSPSC codes, they typically reflect public health program support, epidemic response needs, and benefit-program management operations.

The geographic spread of recent activity under this code includes Florida and Texas, though the opportunities posted show minimal recent purchasing volume for mazipredone hydrochloride specifically. Seminole County released its naloxone procurement (IFB60459723LAS) as a competitive IFB on June 30, 2026, with a response deadline of July 26, 2023 — a discrepancy suggesting data quality issues in the source — requiring annual delivery of 1,900 naloxone units and 800 drug deactivation systems with quarterly fulfillment to the Seminole County Community Health Building in Sanford, Florida, with all shipping included. The Texas RFI (HHS0017013) posted April 3, 2026, pursues vendor market intelligence on direct-to-manufacturer prescription programs for the state's self-insured health plans and employee benefit populations, representing early-stage procurement exploration rather than active demand for a single pharmaceutical commodity. The code shows limited recent activity aligned to mazipredone hydrochloride procurement; vendors should monitor state pharmaceutical benefit manager solicitations and emergency/public health agency RFPs for relevant opportunities in this family.